2,961
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Immune Checkpoint Inhibitor-Induced Uveitis

, MD, PhD, MPH, , MD & , MD

References

  • Douglas VP, Douglas KAA, Cestari DM. Immune checkpoint inhibitors: what neuro-ophthalmologists need to know. Curr Opin Ophthalmol. 2019;30(6):426–433. doi:10.1097/ICU.0000000000000608.
  • Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
  • Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294. doi:10.1097/CCO.0000000000000296.
  • Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. 2018 Aug;13(8):1076–1082. doi:10.1016/j.jtho.2018.04.031.
  • Cohen AF, Lhote R, Amoura A, et al. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med. 2019 Oct 15. doi:10.1111/joim.12991. Online ahead of print.
  • Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest. 2018 Sep;154(3):664–677. doi:10.1016/j.chest.2018.03.056.
  • Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2019 Apr 23:1–6. doi:10.1080/09273948.2019.1583347. Online ahead of print. [Epub ahead of print].
  • Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm. 2020 Jul 9:1–6. doi:10.1080/09273948.2020.1766082. Online ahead of print. PMID: 32643982 [Epub ahead of print].
  • Tsui E, Gonzales JA. Retinal vasculitis associated with ipilimumab. Ocul Immunol Inflamm. 2019 Jul 17:1–3. doi:10.1080/09273948.2019.1610460. Online ahead of print. PMID: 31314622 [Epub ahead of print].
  • Lee J, Shin JY, Lee JS, Lee SC, Hong MH, Lee CS. Recurrent sympathetic ophthalmia with annular choroidal detachment after pembrolizumab treatment: a case report. Ocul Immunol Inflamm. 2019 Jul 1:1–4. doi:10.1080/09273948.2019.1604975. Online ahead of print. PMID: 31260339 [Epub ahead of print].
  • Ahmad TR, Doan T, Gonzales JA, Acharya NR, Tsui E. Clinical course of preexisting uveitis during treatment of lung cancer with durvalumab. Ocul Immunol Inflamm. 2020 May 18;28(4):566–570. doi:10.1080/09273948.2019.1678652. Epub 2019 Nov 11. [Epub ahead of print].
  • Yoshida M, Kunikata H, Nakazawa T. Intraocular concentrations of cytokines and chemokines in a unique case of nivolumab-induced uveitis. Ocul Immunol Inflamm. 2019 Apr 23:1–4. doi:10.1080/09273948.2019.1582785. Online ahead of print. PMID: 31012778 [Epub ahead of print].
  • Fierz FC, Meier F, Chaloupka K, Böni C. Intraocular inflammation associated with new therapies for cutaneous melanoma - case series and review. Klin Monbl Augenheilkd. 2016;233(4):540–544. doi:10.1055/s-0042-102668.
  • Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer. 2014;2(1):41. doi:10.1186/s40425-014-0041-1.
  • Aaberg MT, Aaberg TM Jr. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. 2017;11(4):348–351. doi:10.1097/ICB.0000000000000368.
  • Diem S, Keller F, Rüesch R, et al. Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother. 2016;39(9):379–382. doi:10.1097/CJI.0000000000000143.
  • Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168(2):121–130. doi:10.7326/M17-2073.
  • Venkat AG, Arepalli S, Sharma S, et al. Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. Br J Ophthalmol. 2020;104(5):703–711. doi:10.1136/bjophthalmol-2019-314403.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.